As of November 7, 2026, Cocrystal Pharma, Inc. is a publicly traded company (Nasdaq: COCP). The largest holder reporting an active stake on Schedule 13D is Opko Health, Inc., at 29.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, November 6, 2026).
Is this your company?
About to sign with, pay or invest in Cocrystal Pharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cocrystal Pharma, Inc. a real, registered company?
- Cocrystal Pharma, Inc. files with the SEC under CIK 1412486 (its SEC filings).
- Its shares are listed under the ticker COCP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Bothell, Washington, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cocrystal Pharma, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Carol L. Brosgart, Director (Form 8-K filed 2026-08-18). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Opko Health, Inc. (filed 2026-11-06).
Who are Cocrystal Pharma, Inc.'s owners and officers?
Cocrystal Pharma, Inc.: incorporated in Delaware; business address in Bothell, Washington; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-06 | Opko Health, Inc. | 29.6% |
| Schedule 13D, 2026-08-07 | Opko Health, Inc. | 29.6% |
| Schedule 13D/A, 2026-08-07 | Phillip Frost, M.D. | 13.9% |
| Schedule 13D/A, 2025-10-30 | Phillip Frost, M.D. | 17.8% |
| Schedule 13D/A, 2025-10-02 | Phillip Frost, M.D. | 10.6% |
Questions about who owns Cocrystal Pharma, Inc.
Who owns Cocrystal Pharma, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Cocrystal Pharma, Inc.: Opko Health, Inc. (29.6%, Schedule 13D/A, filed 2026-11-06) and Phillip Frost, M.D. (13.9%, Schedule 13D/A, filed 2026-08-07).
Who are the largest shareholders of Cocrystal Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Cocrystal Pharma, Inc. on this page are Opko Health, Inc. (29.6%) and Phillip Frost, M.D. (13.9%).
When did Opko Health, Inc. buy into Cocrystal Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Opko Health, Inc. on this page is the Schedule 13D, filed 2026-08-07, reporting 29.6%; its latest, Schedule 13D/A filed 2026-11-06, reports 29.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cocrystal Pharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cocrystal Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cocrystal Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-18 | Carol L. Brosgart | Director | appointed | |
| Form 8-K, 2026-06-09 | James Sapirstein | Chief Executive Officer | appointed |
Which insiders own Cocrystal Pharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 2,660,242 shares (13.8% of shares outstanding) (Form 4, 2024-10-11).
- Frost Phillip MD ET AL, a director and 10% owner: 2,020,651 shares (10.5% of shares outstanding), 27,100 held directly and 1,993,551 indirectly (Form 4, 2026-08-06).
- , a director: 1,383,009 shares (7.2% of shares outstanding) (Form 4, 2025-10-30).
- , the chief executive and president: 76,355 shares (0.40% of shares outstanding) (Form 4, 2024-10-11).
- , a director: 67,878 shares (0.35% of shares outstanding), 28,109 held directly and 39,769 indirectly (Form 4, 2024-10-11).
Shares outstanding: 19,263,200 as of 2026-08-13, from the company's latest SEC cover page.
How much has Cocrystal Pharma, Inc. raised?
Latest IPO step: Cocrystal Pharma, Inc. filed to go public (S-1, 2025-09-19).
IPO filings: S-1, 2025-09-19; ticker COCP on Nasdaq Capital Market.
Keep reading
More on Cocrystal Pharma, Inc. and the records around it.
Cocrystal Pharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Aug 2026
Companies that share a holder
- Phillip Frost, M.D. also filed stake reports on 3 other companies: Safe Pro Group Inc. (Sep 2026), Fluent, Inc. (Jan 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cocrystal-pharma